2023-05-312024-05-312024-05-31false14906853ADHD CLINICAL SOLUTIONS LIMITED2025-01-08falseiso4217:GBPxbrli:pure149068532023-05-31149068532024-05-31149068532023-05-312024-05-31149068532023-05-30149068532023-05-30149068532023-05-302023-05-3014906853bus:SmallEntities2023-05-312024-05-3114906853bus:AuditExempt-NoAccountantsReport2023-05-312024-05-3114906853bus:FullAccounts2023-05-312024-05-3114906853bus:PrivateLimitedCompanyLtd2023-05-312024-05-3114906853core:WithinOneYear2024-05-3114906853core:AfterOneYear2024-05-3114906853core:WithinOneYear2023-05-3014906853core:AfterOneYear2023-05-3014906853core:ShareCapital2024-05-3114906853core:SharePremium2024-05-3114906853core:RevaluationReserve2024-05-3114906853core:OtherReservesSubtotal2024-05-3114906853core:RetainedEarningsAccumulatedLosses2024-05-3114906853core:ShareCapital2023-05-3014906853core:SharePremium2023-05-3014906853core:RevaluationReserve2023-05-3014906853core:OtherReservesSubtotal2023-05-3014906853core:RetainedEarningsAccumulatedLosses2023-05-3014906853core:LandBuildings2024-05-3114906853core:PlantMachinery2024-05-3114906853core:Vehicles2024-05-3114906853core:FurnitureFittings2024-05-3114906853core:OfficeEquipment2024-05-3114906853core:NetGoodwill2024-05-3114906853core:IntangibleAssetsOtherThanGoodwill2024-05-3114906853core:ListedExchangeTraded2024-05-3114906853core:UnlistedNon-exchangeTraded2024-05-3114906853core:LandBuildings2023-05-3014906853core:PlantMachinery2023-05-3014906853core:Vehicles2023-05-3014906853core:FurnitureFittings2023-05-3014906853core:OfficeEquipment2023-05-3014906853core:NetGoodwill2023-05-3014906853core:IntangibleAssetsOtherThanGoodwill2023-05-3014906853core:ListedExchangeTraded2023-05-3014906853core:UnlistedNon-exchangeTraded2023-05-3014906853core:LandBuildings2023-05-312024-05-3114906853core:PlantMachinery2023-05-312024-05-3114906853core:Vehicles2023-05-312024-05-3114906853core:FurnitureFittings2023-05-312024-05-3114906853core:OfficeEquipment2023-05-312024-05-3114906853core:NetGoodwill2023-05-312024-05-3114906853core:IntangibleAssetsOtherThanGoodwill2023-05-312024-05-3114906853core:ListedExchangeTraded2023-05-312024-05-3114906853core:UnlistedNon-exchangeTraded2023-05-312024-05-3114906853core:MoreThanFiveYears2023-05-312024-05-3114906853core:Non-currentFinancialInstruments2024-05-3114906853core:Non-currentFinancialInstruments2023-05-3014906853dpl:CostSales2023-05-312024-05-3114906853dpl:DistributionCosts2023-05-312024-05-3114906853core:LandBuildings2023-05-312024-05-3114906853core:PlantMachinery2023-05-312024-05-3114906853core:Vehicles2023-05-312024-05-3114906853core:FurnitureFittings2023-05-312024-05-3114906853core:OfficeEquipment2023-05-312024-05-3114906853dpl:AdministrativeExpenses2023-05-312024-05-3114906853core:NetGoodwill2023-05-312024-05-3114906853core:IntangibleAssetsOtherThanGoodwill2023-05-312024-05-3114906853dpl:GroupUndertakings2023-05-312024-05-3114906853dpl:ParticipatingInterests2023-05-312024-05-3114906853dpl:GroupUndertakingscore:ListedExchangeTraded2023-05-312024-05-3114906853core:ListedExchangeTraded2023-05-312024-05-3114906853dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-05-312024-05-3114906853core:UnlistedNon-exchangeTraded2023-05-312024-05-3114906853dpl:CostSales2023-05-302023-05-3014906853dpl:DistributionCosts2023-05-302023-05-3014906853core:LandBuildings2023-05-302023-05-3014906853core:PlantMachinery2023-05-302023-05-3014906853core:Vehicles2023-05-302023-05-3014906853core:FurnitureFittings2023-05-302023-05-3014906853core:OfficeEquipment2023-05-302023-05-3014906853dpl:AdministrativeExpenses2023-05-302023-05-3014906853core:NetGoodwill2023-05-302023-05-3014906853core:IntangibleAssetsOtherThanGoodwill2023-05-302023-05-3014906853dpl:GroupUndertakings2023-05-302023-05-3014906853dpl:ParticipatingInterests2023-05-302023-05-3014906853dpl:GroupUndertakingscore:ListedExchangeTraded2023-05-302023-05-3014906853core:ListedExchangeTraded2023-05-302023-05-3014906853dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-05-302023-05-3014906853core:UnlistedNon-exchangeTraded2023-05-302023-05-3014906853core:NetGoodwill2024-05-3114906853core:IntangibleAssetsOtherThanGoodwill2024-05-3114906853core:LandBuildings2024-05-3114906853core:PlantMachinery2024-05-3114906853core:Vehicles2024-05-3114906853core:FurnitureFittings2024-05-3114906853core:OfficeEquipment2024-05-3114906853core:AfterOneYear2024-05-3114906853core:WithinOneYear2024-05-3114906853core:ListedExchangeTraded2024-05-3114906853core:UnlistedNon-exchangeTraded2024-05-3114906853core:ShareCapital2024-05-3114906853core:SharePremium2024-05-3114906853core:RevaluationReserve2024-05-3114906853core:OtherReservesSubtotal2024-05-3114906853core:RetainedEarningsAccumulatedLosses2024-05-3114906853core:NetGoodwill2023-05-3014906853core:IntangibleAssetsOtherThanGoodwill2023-05-3014906853core:LandBuildings2023-05-3014906853core:PlantMachinery2023-05-3014906853core:Vehicles2023-05-3014906853core:FurnitureFittings2023-05-3014906853core:OfficeEquipment2023-05-3014906853core:AfterOneYear2023-05-3014906853core:WithinOneYear2023-05-3014906853core:ListedExchangeTraded2023-05-3014906853core:UnlistedNon-exchangeTraded2023-05-3014906853core:ShareCapital2023-05-3014906853core:SharePremium2023-05-3014906853core:RevaluationReserve2023-05-3014906853core:OtherReservesSubtotal2023-05-3014906853core:RetainedEarningsAccumulatedLosses2023-05-3014906853core:NetGoodwill2023-05-3014906853core:IntangibleAssetsOtherThanGoodwill2023-05-3014906853core:LandBuildings2023-05-3014906853core:PlantMachinery2023-05-3014906853core:Vehicles2023-05-3014906853core:FurnitureFittings2023-05-3014906853core:OfficeEquipment2023-05-3014906853core:AfterOneYear2023-05-3014906853core:WithinOneYear2023-05-3014906853core:ListedExchangeTraded2023-05-3014906853core:UnlistedNon-exchangeTraded2023-05-3014906853core:ShareCapital2023-05-3014906853core:SharePremium2023-05-3014906853core:RevaluationReserve2023-05-3014906853core:OtherReservesSubtotal2023-05-3014906853core:RetainedEarningsAccumulatedLosses2023-05-3014906853core:AfterOneYear2023-05-312024-05-3114906853core:WithinOneYear2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:CostValuation2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-312024-05-3114906853core:Non-currentFinancialInstrumentscore:CostValuation2024-05-3114906853core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-05-3114906853core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-05-3114906853core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-05-3114906853core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-05-3114906853core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-05-3114906853core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-05-3114906853core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-05-3114906853core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-05-3114906853core:Non-currentFinancialInstrumentscore:CostValuation2023-05-3014906853core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-3014906853core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-3014906853core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-3014906853core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-3014906853core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-3014906853core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-3014906853core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-3014906853core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-3014906853bus:Director12023-05-312024-05-31

ADHD CLINICAL SOLUTIONS LIMITED

Registered Number
14906853
(England and Wales)

Unaudited Financial Statements for the Period ended
31 May 2024

ADHD CLINICAL SOLUTIONS LIMITED
Company Information
for the period from 31 May 2023 to 31 May 2024

Director

ASIMENG-GYAN, Alfred

Company Secretary

ASIMENG-GYAN, Alfred

Registered Address

5 Malvern Terrace
Edmonton
N9 9PP

Registered Number

14906853 (England and Wales)
ADHD CLINICAL SOLUTIONS LIMITED
Statement of Financial Position
31 May 2024

Notes

2024

£

£

Current assets
Cash at bank and on hand23,353
23,353
Creditors amounts falling due within one year3(10,400)
Net current assets (liabilities)12,953
Total assets less current liabilities12,953
Net assets12,953
Capital and reserves
Called up share capital100
Profit and loss account12,853
Shareholders' funds12,953
The financial statements were approved and authorised for issue by the Director on 8 January 2025, and are signed on its behalf by:
ASIMENG-GYAN, Alfred
Director
Registered Company No. 14906853
ADHD CLINICAL SOLUTIONS LIMITED
Notes to the Financial Statements
for the period ended 31 May 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Going concern
After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
2.Average number of employees

2024
Average number of employees during the year0
3.Creditors: amounts due within one year

2024

£
Trade creditors / trade payables171
Bank borrowings and overdrafts487
Taxation and social security7,941
Accrued liabilities and deferred income1,801
Total10,400